NX-2127

NX-2127 · Nurix Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NX-2127, covering 2026-03-20 to 2026-03-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]